BioSpace News Archive

AbCellera (Nasdaq: ABCL) will announce its third quarter 2022 financial results on Tuesday, November 8, 2022, and hold an earnings conference call at 2:00 p.m. Pacific Time (5:00 p.m. Eastern Time) the same day.

Aziyo Biologics, Inc. announced key promotions and new hires that solidify its position as a leader in treatment options for patients receiving implantable medical devices and other surgical procedures.

Travere Therapeutics, Inc. announced that on October 10, 2022, the Compensation Committee of its Board of Directors granted inducement equity grants to seven new employees, consisting of inducement restricted stock units, or RSUs, covering an aggregate of 25,750 shares of its common stock.

WuXi Biologics (“WuXi Bio”) (2269.HK) and Toregem BioPharma today announced that they have signed a Memorandum of Understanding (MOU) to form a strategic partnership in the development of TRG035, a monoclonal antibody targeting USAG-1 for the treatment of congenital adentia.

Intermountain Forensics, experts in cold case DNA analysis, announced the addition of a dedicated satellite lab for forensic genetic genealogy with new partner Astrea Forensics.

Ascend Performance Materials announced a new portfolio of medical grade nylon 6,6 resins and engineered materials for the healthcare market under its HiDura™ brand.

Todos Medical, Ltd., a comprehensive medical diagnostics and related solutions company, provided a corporate update for shareholders.

EnteroBiotix Limited, the premier full-spectrum microbiome therapeutics company, today announced that it has been granted a Manufacturer’s licence for Investigational Medicinal Products (IMP) by the Medicines and Healthcare Products Regulatory Agency (MHRA) to manufacture microbiome product candidates for clinical trials

The Family Heart Foundation, a leading research and advocacy organization, shared results from an analysis of patients in its CASCADE FH® Registry showing that children with homozygous familial hypercholesterolemia are diagnosed earlier and have much higher untreated low-density lipoprotein cholesterol than adults with HoFH.

BD, a leading global medical technology company, was named to Forbes’ 2022 list of the World’s Best Employers.